Recruiting Atopic Dermatitis Studies in Lafayette
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. The purpose of this st...
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atop...
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tu...
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread...
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
TARA-002-101-Ph2 is an open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1...
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors...
About Atopic Dermatitis Clinical Trials in Lafayette
Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.
There are currently 6 atopic dermatitis clinical trials recruiting participants in Lafayette, IN. These studies are seeking a combined 3,356 participants. Research is being sponsored by Sanofi, BicycleTx Limited, Merck Sharp & Dohme LLC and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Atopic Dermatitis Clinical Trials in Lafayette — FAQ
Are there atopic dermatitis clinical trials in Lafayette?
Yes, there are 6 atopic dermatitis clinical trials currently recruiting in Lafayette, IN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Lafayette?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lafayette research site will contact you about next steps.
Are clinical trials in Lafayette free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lafayette studies also compensate for your time and travel.
What atopic dermatitis treatments are being tested?
The 6 active trials in Lafayette are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.
Data updated March 2, 2026 from ClinicalTrials.gov